Using MSCs for Chronic Active Antibody Mediated Rejection
Launched by SHAHID BEHESHTI UNIVERSITY OF MEDICAL SCIENCES · May 27, 2025
Trial Information
Current as of June 26, 2025
Not yet recruiting
Keywords
ClinConnect Summary
This clinical trial is studying the use of mesenchymal stem cells (MSCs) as a treatment for patients who have experienced chronic active antibody-mediated rejection (AMR) after receiving a kidney transplant. AMR is a condition where the body’s immune system attacks the transplanted kidney, making it difficult for the organ to function properly. The goal of this study was to see if adding MSC therapy to the usual treatment could help improve kidney function and reduce rejection.
To be eligible for this trial, patients need to have a confirmed diagnosis of chronic active AMR after their kidney transplant. Participants would receive MSCs derived from their own bone marrow after they complete their standard treatments, and they would be followed for up to 12 months to monitor their health and kidney function. However, it's important to note that the trial was stopped early due to some serious side effects in one patient, and no improvements were seen in kidney function for the patients who participated. This means that more investigation is needed to understand the safety and effectiveness of this treatment.
Gender
ALL
Eligibility criteria
- Inclusion Criteria:
- • chronic active antibody mediated rejection in kidney transplanted recipients
- Exclusion Criteria:
- • -
About Shahid Beheshti University Of Medical Sciences
Shahid Beheshti University of Medical Sciences, located in Tehran, Iran, is a leading institution dedicated to advancing healthcare through innovative research and education. Renowned for its commitment to medical excellence, the university actively sponsors clinical trials aimed at improving patient outcomes and enhancing medical practices. With a multidisciplinary approach, it collaborates with healthcare professionals and researchers to explore new treatments and interventions, contributing significantly to the global body of medical knowledge. The institution is dedicated to upholding the highest ethical standards in research, ensuring the safety and well-being of participants while fostering a culture of scientific inquiry and discovery.
Contacts
Jennifer Cobb
Immunology at National Institute of Allergy and Infectious Diseases (NIAID)
Locations
Patients applied
Timeline
First submit
Trial launched
Trial updated
Estimated completion
Not reported